For Immediate Release, Covington, KY May 13, 2020 Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have been accepted for oral or poster presentation: Oral Presentation Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial. ... Read More

FOR IMMEDIATE RELEASE [Covington, KY May 6, 2020] Bexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG). DIPG primarily affects children, with most diagnoses occurring between 5 ... Read More

FOR IMMEDIATE RELEASE [Covington, KY~ January 15, 2020] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that Dr. Ray Takigiku, Founder and CEO of the Company will present an overview and recent advancements of its lead compound, BXQ-350 in the Immunotherapy Showcase of the PMWC 2020 conference, ... Read More

Clinical results support strong safety and tolerability for BXQ-350. Topline results support progression into Phase II studies. FOR IMMEDIATE RELEASE Covington, KY ~ 4 September 2019 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature a clinical poster presentation at the National Organization for ... Read More

FOR IMMEDIATE RELEASE Covington, KY ~ March 5, 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has exceeded expectations in screening and enrollment at their 4 trial sites. In the first few weeks of opening Part 3, over 20 GI and ... Read More

FOR IMMEDIATE RELEASE Covington, KY ~ February 22, 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today the opening of Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer. This trial was designed to determine the maximum tolerated dose of BXQ-350 and to characterize its safety and pharmacokinetics. The Phase I ... Read More

FOR IMMEDIATE RELEASE Covington, KY – 22 February 2019 Dr. Ray Takigiku, Founder and CEO of Bexion Pharmaceuticals, Inc. was honored as a finalist in the category of “Entrepreneur” of the Year by the Cincinnati Business Courier at the 2019 Healthcare Hero Awards Celebration. These annual awards honor individuals and organizations that have improved the ... Read More

FOR IMMEDIATE RELEASE Covington, KY ~ 19 November 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that a clinical oral report followed by poster review and a second case study poster were presented at the Society of Neuro-Oncology (SNO) Annual Meeting held November 16-18 in New ... Read More

National Cancer Institute (NCI) Selects Bexion as a Presenting Company FOR IMMEDIATE RELEASE [Covington, KY ~ October 18, 2018] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announces that Dr. Ray Takigiku, Founder and CEO of the Company presented recently at the 15th Annual BioNetwork Partnering Summit, held ... Read More

CancerFree KIDS Awards Nationwide Children’s Hospital Monies to Initiate Pediatric Trial FOR IMMEDIATE RELEASE Covington, KY, June 19, 2018 Sometimes things come full circle. Fourteen years ago, CancerFree KIDS awarded its very first research grant to a young investigator at Cincinnati Children’s Hospital Medical Center (CCHMC) to study a long shot idea that no one ... Read More